DOCS
Doximity, Inc.
DOCS trails on the overall score without a compensating advantage in the available component scores.
OSCR
Oscar Health, Inc.
OSCR has the edge over DOCS overall, supported by stronger fundamentals.
DOCS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Unavailable | |
| Strong |
DOCS's profitability and balance sheet are currently healthy, and its revenue is stable. There isn't enough data to rate its cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
DOCS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 23x | $33.20 | — |
| Cheap | 35x | $24.67 | -26% |
| Current | 47x | $33.20 | — |
| Fair | 49x | $35.12 | +5.8% |
| Expensive | 63x | $45.04 | +36% |
Historical ranges are pointers, not guarantees.
DOCS's PE is in its fair range at 47x. On analysts' estimates for next year's earnings, today's price would be 23x, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over DOCS in the historical PE scenario, which offers more potential upside but is not a forecast.
DOCS Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Growth | |
| Weakening | |
| Moderate | |
| Moderate |
Analysts expect DOCS's revenue to grow, but its profitability to weaken.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over DOCS on the outlook, with more favorable earnings and profitability expectations.
DOCS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.44 | +103% |
| Q3 2026 | $0.71 | -44% |
| Q2 2026 | $0.84 | -28% |
| Q1 2026 | $0.98 | -12% |
| Q4 2025 | $1.20 | +20% |
| Q3 2025 | $1.26 | +45% |
| Q2 2025 | $1.17 | +46% |
| Q1 2025 | $1.11 | +54% |
| Q4 2024 | $1.00 | +49% |
DOCS has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
DOCS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $174.5M | +3.6% |
| Q2 2026 | $156.6M | +7.3% |
| Q1 2026 | $145.4M | +5.1% |
| Q4 2025 | $185.1M | +9.8% |
| Q3 2025 | $168.5M | +23% |
| Q2 2025 | $145.9M | +15% |
| Q1 2025 | $138.3M | +17% |
| Q4 2024 | $168.6M | +25% |
DOCS's revenue has grown year over year every quarter since late 2020: $175M last quarter, up 3.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 25% | -13 points |
| Q2 2026 | 21% | -16 points |
| Q1 2026 | 17% | -18 points |
| Q4 2025 | 39% | -8.5 points |
| Q3 2025 | 38% | -1.1 points |
| Q2 2025 | 37% | +1 points |
| Q1 2025 | 35% | -0.3 points |
| Q4 2024 | 47% | +4.1 points |
DOCS has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over DOCS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
DOCS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $93.3M | -0.7% |
| Q2 2026 | $41.9M | -32% |
| Q4 2025 | $60.9M | -6.6% |
| Q3 2025 | $93.9M | +37% |
| Q2 2025 | $62.1M | +51% |
| Q1 2025 | $98.5M | +54% |
| Q4 2024 | $65.2M | +30% |
| Q3 2024 | $68.3M | +432% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with DOCS at up 65%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
DOCS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.8% | -3.4M shares |
| 1 year | -6.4% | -12.9M shares |
| 3 years | -10% | -21.2M shares |
| 5 years | -13% | -28.9M shares |
| Available history | +3.4% | +6.1M shares |
DOCS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $54.2M |
| Q2 2026 | $91.6M |
| Q1 2026 | $90.5M |
| Q4 2025 | $196.9M |
| Q3 2025 | $21.9M |
| Q2 2025 | $122.4M |
| Q1 2025 | $26.8M |
| Q4 2024 | $19.3M |
DOCS spent $433M buying back its own shares over the past year, up 128% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
DOCS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -1.3x | Net Cash |
| Q1 2026 | -1.0x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.7x | Net Cash |
| Q2 2025 | -0.6x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
DOCS has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over DOCS on leverage, with a lower net debt burden relative to earnings.
DOCS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.2 | Neutral |
| Stochastic | 69.8 | Neutral |
DOCS's weekly RSI is 64 (neutral) and its Stochastic is 70 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
DOCS PE vs Healthcare Sector
| Metric | DOCS | Sector median | Relative |
|---|---|---|---|
| PE | 47x | 26x | 81% above |
| PE % | 45 | 37 | 8 pts above |
DOCS is trading at 47x earnings, a 81% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over DOCS on valuation relative to its sector.
DOCS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.0 | 7.3% above |
| 20 week MA | $26.8 | 24% above |
| 50 week MA | $28.1 | 18% above |
| 100 week MA | $44.7 | 26% below |
| 200 week MA | $38.1 | 13% below |
DOCS has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 13% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over DOCS on trend strength, trading above more of its moving averages.
DOCS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $56.0 | $51.5 | -7.9% |
| 2022 | $51.5 | $34.2 | -34% |
| 2023 | $34.2 | $28.0 | -18% |
| 2024 | $28.0 | $57.8 | +106% |
| 2025 | $57.8 | $43.7 | -24% |
| 2026 YTD | $43.7 | $33.2 | -24% |
DOCS has finished lower in four of the last five years. It's down 24% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over DOCS on returns for 2026, with the stronger performance.